Development of a SARS‐CoV‐2 viral dynamic model for patients with COVID‐19 based on the amount of viral RNA and viral titer

Author:

Yamaguchi Daichi1ORCID,Shimizu Ryosuke1ORCID,Kubota Ryuji1ORCID

Affiliation:

1. Clinical Pharmacology & Pharmacokinetics Shionogi & Co., Ltd. Osaka Japan

Abstract

AbstractThe target‐cell limited model, which is one of the mathematical modeling approaches providing a quantitative understanding of viral dynamics, has been applied to describe viral RNA profiles of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in previous studies. However, these models have been developed mainly using patient data from the early phase of the pandemic. Furthermore, no reports focused on the profiles of the viral titer. In this study, the dynamics of both viral RNA and viral titer were characterized using data reflecting the current clinical situation in which the Omicron variant has become epidemic and vaccines for SARS‐CoV‐2 have become available. Consecutive data for 5212 viral RNA levels and 5216 viral titers were obtained from 720 patients with coronavirus disease 2019 (COVID‐19) in a phase II/III study for ensitrelvir. Our model assumed that productively infected cells would produce only infectious viruses, which could be transformed into non‐infectious viruses, and has been used to describe the dynamics of both viral RNA levels and viral titer. The time from infection to symptom onset (tinf) of unvaccinated patients was estimated to be 3.0 days, which was shorter than that of the vaccinated patients. The immune‐related parameter as a power function for the vaccinated patients was 1.1 times stronger than that for the unvaccinated patients. Our model allows the prediction of the viral dynamics in patients with COVID‐19 from the time of infection to symptom onset. Vaccination status was identified as a factor influencing tinf and the immune function.

Publisher

Wiley

Reference50 articles.

1. World Health Organization.WHO Coronavirus disease (COVID‐19) dashboard. Accessed November 10 2023.https://covid19.who.int/

2. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern

3. World Health Organization.Classification of Omicron (B.1.1.529): SARS‐CoV‐2 variant of concern. Accessed November 10 2023.https://www.who.int/news/item/26‐11‐2021‐classification‐of‐omicron‐(b.1.1.529)‐sars‐cov‐2‐variant‐of‐concern

4. SARS‐CoV‐2 Omicron variant: Immune escape and vaccine development

5. Omicron and Delta variant of SARS‐CoV‐2: A comparative computational study of spike protein

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3